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Abstract Renal biopsy is a very important diagnostic tool
in the evaluation of renal diseases. However, bleeding
remains to be one of the most serious complications in this
procedure. Many new techniques have been improved to
make it safer. The risk factors and predictors of bleeding
after percutaneous renal biopsy have been extensively
reported in many literatures, and generally speaking, the
common risk factors for renal biopsy complications focus
on hypertension, high serum creatinine, bleeding diatheses,
amyloidosis, advanced age, gender and so on. Our primary
purpose of this review is to summarize current measures in
recent years literature aiming at minimizing the bleeding
complication after the renal biopsy, including the drug
application before and after renal biopsy, operation details
in percutaneous renal biopsies, nursing and close moni-
toring after the biopsy and other kinds of biopsy methods.
Keywords Renal biopsy  Bleeding complication 
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Introduction
Since the first successful percutaneous renal biopsy in
1950s, renal biopsy has been an essential procedure in
establishing the histological diagnosis, adequate therapy and
prognosis of kidney diseases [1–4]. With the help of ultra-
sound guidance and spring-loaded biopsy needle, this pro-
cedure has became safer, but like many invasive procedures,
renal biopsy accompanies with the risk of potential com-
plications such as bleeding, infection, pain, loss of kidney
and even death, while bleeding complications are the most
common one. Post-renal biopsy bleeding complications are
classified as either major or minor. Major complications
include hemorrhage requiring transfusion, bleeding with
necessity of nephrectomy and death. The frequency of major
hemorrhage has ranged from 0 to 6 % in different studies [1,
5, 6]. Minor complications are defined as gross hematuria or
subcapsular perinephric hematoma which will spontane-
ously be resolved without need for further intervention. For
example, according to the survey of Shidham et al. [1], the
incidence of post-renal biopsy bleeding contains the fol-
lowing: gross hematuria, 1.9 %; hematoma, 0.9 %; and
blood transfusion, 2.5 %. Also, the meta-analysis by Corapi
et al. [7] summaries that the complication rate of macro-
scopic hematuria is 3.5 % (95 % CI 2.2–5.1 %), and
erythrocyte transfusion is 0.9 % (95 % CI 0.4–1.5 %).
Besides, in the studies by Daram et al. [8], around a quarter
of patients had [10 % decline in hematocrit at 24 h,
requiring blood transfusion in 3.6–9 % of the patients and an
incidence of gross hematuria of 3.6–17 %. A large series of
[9,000 biopsies in pediatric and adult patients is recently
reported by Tondel et al. [9], and their study shows that gross
hematuria appears after biopsy in 1.9 % of the patients and
0.9 % of patients need blood transfusion. The frequencies
are 1.9 and 0.9 % in adults and 1.7 and 0.1 % in children. All
of these studies show that though renal biopsy has became
safer, it is still not without risk.
Risk factors on post-biopsy bleeding
To determine the effect of various risk factors on post-
biopsy bleeding, many retrospective cohort studies have
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been performed. Generally speaking, the common risk
factors for renal biopsy complications focus on hyperten-
sion, high serum creatinine, bleeding diatheses, amyloi-
dosis, advanced age, gender and so on, though some factors
are still under debate [1, 2, 7–11]. Among the many risk
factors, parts of them are modifiable, such as hypertension
and bleeding diatheses, which can be modified by corre-
sponding drugs. So the more we know about the risk fac-
tors for bleeding complications of renal biopsy, the better
measures we can take to reduce the complication rates.
Hypertension
Blood pressure was significantly higher in patients with
complications, and it was regarded as a risk factor for
bleeding complications independently of all other variables
by logistic multivariate analysis [25]. The study of Shid-
ham et al. [1] showed that the risk of bleeding increased
with high systolic blood pressure (SBP), diastolic blood
pressure (DBP) or mean arterial pressure (MAP). For
example, the risk of bleeding was 10.7 % when SBP
[160 mmHg compared with 5.3 % when the SBP
\160 mmHg (P = 0.03). Similarly, the risk was 12.5 %
when the MAP [120 mmHg compared with 5.1 % when
the MAP \120 mmHg (P = 0.009).
High serum creatinine
The serum creatinine also affected the bleeding compli-
cations after renal biopsy. Patients with major complica-
tions had higher serum creatinine levels when compared
with those who did not. In the study of Whittier et al. [10],
multivariate analysis using logistic regression showed that
serum creatinine at baseline predictive of a complication
and patients with a serum creatinine [5.0 mg/dl were 2.3
times as likely to have a complication (odds ratio, 2.3;
95 % CI 1.3–4.1; P \ 0.005). In another study, for patients
with creatinine [2 mg/dl, the risk ratio for post-biopsy
bleeding (PBB) was 5.89 when compared with patients
with creatinine \2 mg/dl, and logistic regression analysis
showed that serum creatinine of[2.0 mg/dl was associated
with an odds ratio of 2.56 (CI 1.48–4.42, P = 0.001) for
PBB [1]. All these similar results showed that the risk of
bleeding postoperatively increases with worsening levels of
renal insufficiency.
Prolonged bleeding time
The role of prolonged bleeding time was controversial.
Previous studies on renal biopsy did not demonstrate a firm
relationship between the bleeding time and bleeding
complications. Eiro et al. [25] performed a research that
pro-thrombin time, activated partial thromboplastin time
and bleeding time were measured routinely in all patients
before performing renal biopsy, and patients who had at
least one abnormal value were regarded as contraindicated.
In the study of Manno et al. [31], baseline partial throm-
boplastin time was significantly higher in patients who
developed post-biopsy bleeding complications compared
with those who did not (102.7 ± 11.8 vs. 100.1 ± 10.0 %,
P = 0.013). However, in the study by Mackinnon et al.
[12], the correction of prolonged bleeding time with pro-
coagulants might not significantly reduce the risk of clin-
ically important bleeding and they warned us that the
administration of a pro-coagulant might increase the risk of
a thrombotic vascular event, and thus, the practice of
administering pro-coagulants routinely to correct a pro-
longed bleeding time should be reassessed. In the study of
van den Hoogen et al. [13], the platelet function analyzer
(PFA) had a higher positive and similar negative predictive
value compared to the bleeding time. When a screening of
the primary hemostasis was performed prior to a renal
biopsy, they recommended using the PFA instead of the
bleeding time (BT).
Histological diagnosis and amyloidosis
The relationship between the histological diagnosis and the
complications of post-renal biopsy had been studied. Fisi
et al. [14] performed a research which showed that in patients
with the diagnosis of diabetic nephropathy or acute tubular
necrosis, the overall complication prevalence was signifi-
cantly lower compared to others, while complication rate
was the highest in patients who suffered from thin basement
membrane syndrome, vasculitis, rapidly progressive glo-
merulonephritis (RPGN) or acute interstitial nephritis.
However, in the latter patients, the higher rate of complica-
tions may be related to the possibility of low glomerular
filtration rate (GFR) because of acute kidney injury in many
of these instances. In the meta-analysis by Corapi et al. [7],
acute kidney injury was related to significantly higher rates
of need for transfusion after renal biopsy (1.1 vs. 0.04 %;
P \ 0.001). The result of another study by Tondel et al. [9]
also showed that low estimated GFR (estimated
GFR = 30–59 ml/min per 1.73 m2 [OR = 4.90
(1.60–14.00)] and estimated GFR\30 ml/min per 1.73 m2
[OR 15.50 (5.60–43.00)]) had higher odds in adjusted ana-
lysis for risk factors for major complication after renal
biopsy. So perhaps the low GFR was a confounding factor
which would make it look like that certain diseases were
linked with higher complication rates. Still, in the latter
patients with a higher risk, stricter post-biopsy monitoring
might be necessary. Amyloidosis was also regarded as an
important risk factor for bleeding complication after renal
biopsy in some studies [25]. To assess its risk, Soares et al.
[15] performed a large retrospective study and their result
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showed that incidences of bleeding after kidney biopsy were
similar between the amyloidosis and control groups (9.9 vs.
10.6 %). They suggested that the doctrine that patients with
amyloid were at a greater risk of hemorrhage after kidney
biopsy appeared to be the result of reporting bias. In fact,
since patients with any systemic amyloidosis could have
widespread small-vessel fragility by direct vessel infiltration
and acquired hemostatic abnormalities caused by coagula-
tion factor deficiency, it was reasonable for us to undertake
the procedure in such patients with great care. So it was
reasonable for us to check the hemostatic condition and
whether hypertension existed in the patients with amyloi-
dosis before the renal biopsy was done.
Age and gender
Other risk factors included that there was a significantly
greater proportion of women compared with men who
developed post-biopsy bleeding complications. In the study
by Manno et al. [31], the increased risk of post-biopsy
bleeding in women might be explained by their different body
composition. The greater percentage of fat mass in women
might be responsible for a tendency for hematoma to expand
in the peri-renal fatty tissue. There was also a variable distri-
bution in the risk of post-biopsy bleeding according to age, as
the incidence of bleeding complication was more in older
patients than in younger ones [16, 25]. A hypothesis was made
in the study by Kohli et al. [16] that the higher incidence of
gross hematuria in the elderly might have been due to the
arterial wall changes related to aging. Due to the near ubiq-
uitous presence of arteriosclerosis in the elderly, the ability of
severed small vessels to undergo vasoconstriction might be
impaired resulting in hematuria. Also, in the study of Whittier
et al. [10], patients with a major complication after biopsy
were older (53 ± 17 vs. 43 ± 18 years; P \ 0.05).
Measures that related to minimizing the bleeding
complications
Despite the understanding of predisposing risk factors,
there is still no definitive way to predict whether one
patient will surely develop a serious complication. In our
review of the literature, we focus on the possible ways
which are in an attempt to minimize the bleeding compli-
cation in post-renal biopsy.
Application of drugs before and after renal biopsy
Antihypertensive drugs
Many studies showed that the hypertension was one of the
important risk factors for post-renal biopsy bleeding, and
thus, controlling the hypertension might help to reduce its
incidence. In order to get hypertension under control before
the biopsy, a calcium channel blocker or nifedipine was
administered prior to renal biopsy to patients with a blood
pressure reading [140/90 mmHg [25, 31]. For example,
Maya et al. [5] performed a research that patients with
uncontrolled hypertension ([160/100 mmHg) were treated
with oral clonidine (0.1 mg) or intravenous hydralazine
(10 mg) to lower their blood pressure prior to the biopsy.
But we should also be cautious that acutely lowering blood
pressure before biopsy using dihydropyridine type calcium
channel blockers had been associated with an increased
risk of bleeding due to vasodilatation and inhibition of
platelet function [16]. However, there have been no sys-
tematic studies in renal biopsy to address this issue.
Desmopressin acetate
Desmopressin has a long history of being used to decrease
the prolonged bleeding time in patients with uremia in an
effort to improve hemostasis. It has also been used in high-
risk patients undergoing kidney biopsy [2, 3, 13, 17].
Manno et al. [18] performed a study to evaluate the effect
of pre-biopsy administration of desmopressin acetate ver-
sus placebo in the incidence of post-biopsy bleeding
complications. In their study patients who received des-
mopressin acetate had significantly decreased the risk of
post-biopsy bleeding (13.7 vs. 30.5 %; P = 0.01), and in
addition, the size of the hematoma, if present, was on
average smaller in the intervention group (median, 208 vs.
380 mm2; P = 0.006). Still, this was a single-center design
study which decreased the generalization of the results and
its external validity. In their study, desmopressin acetate
was used for all patients regardless of GFR, whereas in
clinical practice, it was probably only used in patients with
significantly deteriorated GFR. More studies are needed to
confirm the effect of pre-biopsy treatment with desmo-
pressin acetate.
Recombinant activated factor VII
In the case report of Maksimovic et al. [19], recombinant
activated factor VII (rFVIIa) was used to treat uncon-
trolled bleeding which was caused by renal biopsy after
unsuccessful treatment with desmopressin. With the
application of rFVIIa, the bleeding stopped immediately.
Thus, a conclusion was made that rFVIIa appeared effi-
cacious and well tolerated in the treatment of post-biopsy
bleeding in a kidney transplant patient with renal failure.
This case report indicates the effectiveness of rFVIIa in
the treatment of uremic patients, though more prospective
studies of its efficacy and safety in such patients are
needed.
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Preventative use of drugs
The preventative use of hemostatic agents in patients
without any coagulation disorder before renal biopsy is
common in some Chinese hospitals, though it may not
often be seen in other countries. The common drugs used
are Reptilase and vitamin K1. After being injected intra-
venously, Reptilase can divide the a-subunit of fibrinogen
into A-peptide and fibrin monomers, the later of which
polymerizes and helps improve hemostasis. Feng HL [20]
reported in his study that before the renal biopsy, 1KU
Reptilase given to the patients by intravenous injection
could effectively reduce the bleeding compared with the
control group (hemoglobin reduction: control group
16 ± 9 g/L vs. treatment group 5 ± 3 g/L; P \ 0.05).
Similar results can be seen in the study of Zhou [21], which
shows that vitamin K1 10 mg used 3 days and Reptilase
1KU used 1 h before and after renal biopsy could effec-
tively reduce the incidence rate of bleeding complication
after the renal biopsy procedures (gross hematuria: control
group 7.5 % vs. treatment group 2.5 %; P \ 0.05). Though
their study results need further confirmation, it presents a
possible approach to deal with the commonly seen bleeding
complication after the renal biopsy.
Antiplatelet agents
Generally speaking, the antiplatelet agents and non-ste-
roidal anti-inflammatory drugs were discontinued 7 days
before the biopsy, which could be seen in a series of ret-
rospective cohort studies [3–5, 14, 16]. For example, the
mean duration of antiplatelet agent cessation was
7.9 ± 2.2 days before and 6.0 ± 3.4 days after renal
biopsy in a French nationwide study [17]. However, in the
study by Mackinnon et al. [12], the ongoing use of anti-
platelet agents was not associated with an increase in the
risk of clinically significant bleeding complications and the
withdrawal of antiplatelet agents had a risk of causing
coronary syndrome. They performed a retrospective study
of 1120 biopsies to define whether it was necessary to stop
antiplatelet agents, and their result showed that stopping
antiplatelet agents before biopsy was associated with a
lower rate of minor complications (31.0 vs. 11.7 %;
P = 0.008), but there was no difference in the rate of major
complications. Atwell et al. [22] also performed a research
about the influence of aspirin on the biopsy, and their result
showed that the incidence of bleeding in patients taking
aspirin within 10 days before biopsy was 0.6 % (18/3,195),
which was not statistically different compared with the
incidence of bleeding in those not taking aspirin (52/
11,986, 0.4 %; P = 0.34). Interestingly, a meta-analysis of
the literature related to peri-procedural aspirin use proved
that an approximately 50 % increase in the bleeding rate in
those taking aspirin at the time of surgery or biopsy [23].
Besides, the platelet function analyzer was recommended
to be used in the screening of primary hemostasis instead of
bleeding time [13]. In fact, whether the antiplatelet agents
and non-steroidal anti-inflammatory drugs should be dis-
continued or not depend on the condition of the patients.
For those without heart disease, it is a better choice for
them to stop antiplatelet agents before the biopsy, while for
those with high risk of coronary syndrome, we need to
balance the risks and benefits of performing biopsy,
bleeding complication and acute coronary syndrome.
Operation details in percutaneous renal biopsies
Post-biopsy complications may be even less frequent with
the use of smaller gauge needles. In the study of Kim et al.
[24], the use of 14-gauge versus 18-gauge in native kidney
renal biopsies had been compared in a randomized trial that
showed a greater incidence of complications in manual
biopsy with 14-gauge needle compared with automated
renal biopsy using 18-gauge guns. Though their study had
been flawed as it may reflect the impact of biopsy tech-
nique rather than needle size, similar results could be seen
in the meta-analysis of Corapi et al. [7], which was that
significantly higher rates of transfusion after renal biopsy
were related to the needle size: 14-gauge compared with
smaller needles (2.1 % vs. 0.5 %; P = 0.009). The study
of Tondel et al. [9] showed that the dominance o f 16- and
18-G needles may result in higher focus on minimizing risk
factors and the acceptance of less tissue per needle pass. In
their study, the median number of glomeruli per subject
was comparable with other studies, while the percentage of
biopsies characterized as representative tissue was in the
same level irrespective of needle size.
The study of Eiro et al. [25] showed that the frequency
of the puncture was not significantly different between
moderate complications and no or mild complications;
however, by logistic multivariate analysis, the frequency
of the puncture was an independent risk factor. The
relationship between the bleeding complications and the
depth of needle insertion was studied. Pasquariello et al.
[26] performed a research that if the trigger was pushed
exactly at the depth previously calculated by a mathe-
matical formula: BW/H less 0.5 (body weight expressed
in hectograms divided by patient height expressed in
centimeters), it would be extremely useful to reduce the
incidence of bleeding complications and allowed an
adequate sampling for diagnostic evaluation in all cases.
Another study also found some positive relationship
between hemoglobin decrease and depth of needle inser-
tion and warned that nephrologists should be cautious of
depth of needle insertion to avoid major hemorrhage
complication [4].
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Some studies showed that there was no inevitable rela-
tionship between the experience of the operator and the
incidence of post-biopsy bleeding. In the study of Maya
et al. [5], the complications rate was low despite their
performance by first-year nephrology fellows. The reason
may be that the use of real-time ultrasound guidance per-
mitted 91 % of the patients to require just one or two
needle passes, which likely contributed to the low major
complication rate. Similar results could be seen in another
study, which showed that the use of the real-time ultra-
sound-guided technique minimized the risk of major
complications even in the hands of inexperienced operators
[27]. In summary, the real-time ultrasound guidance makes
this operation safer.
Nursing and close monitoring after the biopsy
Fisi et al. [14] in their study showed that after the renal
biopsy, patients remaining in bed lying on their backs all
the time with a sandbag under the site of puncture for 4 h
was a way to reduce the complications and a fluid intake of
at least 3L was recommended in this period. In fact, this
was also a common measure taken to deal with post-renal
biopsy complications in some Chinese hospitals, for
example, a sandbag or abdominal compression belts were
used to press the puncture site for 6 h with blood pressure
monitoring and the urinary catheter might be inserted in
order to reduce the patients’ movements, which may cause
bleeding [21, 28, 29]. Few studies showed the influence of
such procedure on the incidence rate of post-renal biopsy
bleeding; however, it had been debated that since kidney
was deep in the body and the pressure of the sandbag
worked on the surface of the back, maybe the hemostatic
effect would not be as perfect as imagine. Besides, the
sandbag would cause discomfort when placed on the back
of the patients on bed. In these aspects, the effectiveness of
this method and its application needs more clinical
observations.
Whittier et al. [10] performed a study on the timing of
the complications and showed that complications happened
in 67 % patients in 8 h, and in 89 % patients at B24 h,
which meant an observation time of up to 24 h was optimal
because an observation period of \8 h meant missing
about 22 % of complications. In another research, if the
patient showed no signs of bleeding complications 18 h
after the biopsy, there was little probability for them to
grow thereafter [25]. These results presented the impor-
tance of the observation of monitoring after the biopsy. As
the utility of early post-renal biopsy ultrasound was useful
in predicting the risk of major bleeding complications,
some studies showed that the ultrasound findings 1 h post-
biopsy were clinically helpful in predicting the bleeding
complication. While the presence of a hematoma at 1 h
post-biopsy was not predictive of a complicated post-
biopsy course, the absence of a hematoma 1 h post-biopsy
was highly predictive of an uncomplicated post-biopsy
course [2]. In the retrospective study by Ishikawa et al. [4],
perirenal hematoma [2 cm immediately after biopsy was
the strongest predictor of more severe anemia the morning
after biopsy. Their findings were similar with other reports
of progressive anemia with larger post-biopsy hematoma
[30]. This indicated that ultrasonographic evaluation of
hematoma size immediately after renal biopsy was useful
in predicting potentially severe blood loss. A conclusion
was also made in the study by Daram et al. [8] that the
degree of decline in Hct at 6 h was predictive of the degree
of decline at 18–24 h. But this result still needs to be
validated in larger prospective studies.
Other kinds of biopsy methods
With the new technologies of real-time ultrasonography for
guiding the procedure and the use of automatic biopsy
needles, percutaneous renal biopsies are well established as
a safe and effective technique for obtaining samples of
renal parenchyma, and it has improved the rate of suc-
cessful diagnosis in over 95 % of cases [32]. However,
absolute and relative contraindications for the percutaneous
approach do exist. When renal histology is necessary for
clinical management but percutaneous biopsy is contrain-
dicated or unsuccessful, other methods of renal biopsy by
experienced physicians may be attempted.
Transjugular renal biopsy
A study was performed to describe the indications for
transjugular renal biopsy (TJRB) and the results showed
that the most common indication was a bleeding diathesis
due to thrombocytopenia or coagulopathy, and other rec-
ognized indications for a TJRB include inability to coop-
erate with the percutaneous procedure, severe
hypertension, a solitary or horseshoe kidney, end-stage
renal disease or bilaterally small kidneys and morbid
obesity [33]. In a large study by Cluzel et al. [34], TJRB
was compared with percutaneous renal biopsies and the
result showed that there was no difference in the diagnostic
yield or in complication rates. Major complications
occurred in *1 % when using both routes. The number of
glomeruli per biopsy was smaller using the TJRB route
(11.2 vs. 9.8; P = 0.361). This reduction in yield probably
resulted from the smaller needle size used for TJRB. Levi
et al. [35] performed a study that their initial experience
with TJRB was similar or better than in prior reports with
regard to both diagnostic yield and complication rates. So
TJRB is recognized as an alternative, safe and effective
technique in patients with renal parenchymal disease.
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However, due to its technical complexity and the smaller
amount of glomeruli retrieved when compared to percuta-
neous biopsy, it should be reserved for high-risk patients.
Open renal biopsy
Alternative methods except transjugular renal biopsy have
also been attempted for obtaining samples of kidney tissue
samples in patients with contraindications for the percuta-
neous approach. The open renal biopsy (surgical approach)
has been established as a safe and effective technique for
obtaining renal tissue. Multiple bilateral renal cysts are a
relative contraindication for the percutaneous approach due
to the risk of complications and the difficulty in obtaining
adequate tissue samples. In these situations, an open renal
biopsy through a posterior or flank incision is a viable
option. However, both the risk of general anesthesia and
the delayed recovery time associated with the open
approach are of obvious concern [32, 36].
Transurethral renal biopsy
There are other less invasive alternatives. A special method
of renal biopsy, the transurethral approach, had been
described [37]. In this case report, a 62-year-old woman
underwent the procedure with an 18-gauge needle via
cystoscopy and 28 glomeruli were retrieved. The patient
was observed for 24 h after the procedure and had a small
subcapsular hematoma when checked by abdominal CT on
routine evaluation. However, the transurethral approach is
seldom mentioned afterward.
Laparoscopic renal biopsy
Laparoscopic renal biopsies can be performed using a ret-
roperitoneal or transperitoneal approach. These biopsy
methods allow for identification of the kidney, and the biopsy
and hemostasis can be performed under direct visualization.
Additionally, it is minimally invasive with very short patient
recovery and convalescence times in the majority of cases.
The retroperitoneoscopy or transperitoneal renal biopsy is in
fact that currently recommended procedure for pediatric
cases. Recently, a technique has been proposed that com-
bines the laparoscopic approach with a percutaneous needle
biopsy. This approach combines the advantages of the per-
cutaneous biopsy with the minimal trauma and low mor-
bidity associated with laparoscopic procedures [36].
Conclusions
The renal biopsy is a very important and useful diagnostic
tool for kidney diseases, and with the development of new
technique, it has become much safer, but the bleeding com-
plication does exist. There are many factors that may affect
the post-biopsy complications, and thus, careful observation
in the hospital is required for some patients with high risk.
Among the many risk factors, parts of them are modifiable, so
the medical data of patients should be checked whether the
above risk factors such as hypertension, abnormality of the
coagulation, high serum creatinine exist and measures
should be taken to get the conditions under control if nec-
essary. Before the renal biopsy, whether the preventive use of
desmopressin acetate or other hemostatic agents should be
adopted depends on the exact effect of it and needs further
clinical trials. Also, whether the antiplatelet agents and non-
steroidal anti-inflammatory drugs should be discontinued or
not depends on the condition of the patients. For those
without heart disease, it is advisable to stop antiplatelet
agents for at least 1 week before the biopsy; however, for
those with high risk of coronary syndrome, we need further
risk benefit analysis. Whenever possible the biopsy proce-
dure should be performed under real-time ultrasound or CT
scan guidance and via an automated spring-loaded biopsy
gun, rather than performed blindly. We should be cautious
about the depth of the needle insertion as to get enough tissue
for histological diagnosis and to avoid much traumatic
damage to the renal parenchyma whose blood flow is abun-
dant. Besides, the close monitoring of the patient in the post-
biopsy period is of great importance. We believe that with the
understanding of the risk factors and the considerate mea-
sures taken, and the use of real-time imaging and automated
gun biopsy needles, the renal biopsy has become a safe
procedure today.
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